2265 Upper Middle Road East
Suite 602
Oakville, ON L6H 0G5
Canada
289-910-0850
https://www.cardiolrx.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees:
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. David G. Elsley MBA | President, CEO & Director | 748.1k | N/A | N/A |
Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA | CFO, Corporate Secretary & Director | 294.8k | N/A | N/A |
Mr. Bernard Lim B.Sc. | Chief Operating Officer | 515.9k | N/A | N/A |
Dr. Andrew Warwick Hamer M.D. | Chief Medical Officer & Head of Research & Development | 746.56k | N/A | 1962 |
Trevor Burns | Investor Relations | N/A | N/A | N/A |
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Cardiol Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.